Alpha Teknova, which provides reagents and other materials for biopharmaceutical R&D applications, raised $96 million by offering 6 million shares at $16, the high end of the range of $14 to $16. The company offered 1 million more shares than anticipated.
Alpha Teknova is a leading provider of critical reagents that enable the discovery, research, development and production of biopharmaceutical products such as drug therapies, novel vaccines, and molecular diagnostics. The company offers three primary product types: pre-poured media plates for cell growth and cloning, liquid cell culture media and supplements for cellular expansion, and molecular biology reagents for sample manipulation, resuspension, and purification. As of March 31, 2021, Alpha Teknova had over 3,000 active customers.
Alpha Teknova plans to list on the Nasdaq under the symbol TKNO. Cowen, and William Blair acted as joint bookrunners on the deal.
